Discontinuing antiparkinson medication in chronic schizophrenics
- 1 January 1981
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 63 (1), 28-32
- https://doi.org/10.1111/j.1600-0447.1981.tb00646.x
Abstract
In a double-blind study of 100 chronic schizophrenic patients, withdrawal of anti-parkinson (AP) medication showed that 44% of the 75 patients who constituted the placebo group (vs. none of the patients on active AP medication) complained strongly of debilitating extrapyramidal symptoms (EPS). Another 22.6% (vs. 8.7% of the patients on active AP medication) displayed disturbing psychotic symptomatology related to EPS. The view that AP medication may be safely withdrawn from chronic schizophrenics was discussed.Keywords
This publication has 5 references indexed in Scilit:
- Assessment of drugs in schizophrenia. Discussion on assessment of drug‐ induced extrapyramidal reactions.British Journal of Clinical Pharmacology, 1976
- AkinesiaArchives of General Psychiatry, 1975
- The many faces of AkathisiaComprehensive Psychiatry, 1975
- Evaluating the Long-Term Need for Antiparkinson Drugs by Chronic SchizophrenicsArchives of General Psychiatry, 1972
- Withdrawal of Antiparkinson DrugsArchives of General Psychiatry, 1971